A randomized, double‐blind, single‐dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab

Abstract To investigate and compare the pharmacokinetic (PK) profiles of MB02 products, before and after optimizing the manufacturing process, and reference bevacizumab to establish bioequivalence between them. In this randomized, double‐blind, single dose, parallel study, 114 healthy male volunteer...

Cijeli opis

Bibliografski detalji

Glavni autori:	C. Schwabe, A. Cole, A. Espigares‐Correa, M. E. Beydon, A. Florez‐Igual, J. Queiruga‐Parada
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2023-04-01
Serija:	Pharmacology Research & Perspectives
Teme:	bevacizumab biosimilar clinical trial MB02 pharmacokinetics safety
Online pristup:	https://doi.org/10.1002/prp2.1070
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!